Akaza Biopharma

Akaza Biopharma is a clinical-stage biotechnology company dedicated to the discovery and development of small molecule therapies for autoimmune and inflammatory diseases. The company's lead program, AKZ-001, is an oral, small molecule inhibitor of RORγt, a master regulator of the Th17 cell lineage and the production of IL-17. By targeting this pathway, Akaza aims to provide effective oral alternatives to injectable biologics for patients suffering from chronic conditions like psoriasis and inflammatory bowel disease. The company was founded by industry veterans and scientific leaders from the Scripps Research Institute and Calibr.